Shares of Liquidia Technologies Inc (LQDA) took an unexpected turn in pre-market trading on Monday, plummeting 5.05% despite the company reporting better-than-expected third-quarter results. This sharp decline has left investors puzzled, given the initially positive reaction to the earnings report.

Liquidia announced impressive Q3 2025 financials, with earnings per share of $(0.04) beating the analyst consensus estimate of $(0.40) by a significant margin. The company's quarterly sales of $54.342 million also surpassed expectations, coming in 188.66% higher than the projected $18.825 million. These results marked a substantial improvement from the same period last year, driven by strong sales of YUTREPIA, Liquidia's inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Initially, the market reacted positively to these results, with Liquidia shares rising 10.1% in early pre-market trading. However, the stock's trajectory quickly reversed, first dropping to a 1.5% decline before accelerating to the current 5.05% plunge. This dramatic shift in investor sentiment, despite the strong financial performance, suggests that other factors may be influencing the stock's movement. Possible explanations could include profit-taking following the initial surge, concerns about future guidance, or broader market trends affecting the biotech sector. As the trading day progresses, investors and analysts will be closely watching for any additional news or insights that might explain this puzzling stock movement.